A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections

Mycoses

Volumn 54, Issue 3, 2011, Pages 234-242

  Yilmaz, Deniz ^a   Balkan, Can ^a   Ay, Yilmaz ^a   Akin, Mehmet ^a   Karapinar, Bulent ^a   Kavakli, Kaan ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Caspofungin; Children; Combined antifungal therapy; Haematologic malignancy; Invasive fungal infection; Voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FUNGUS ANTIGEN; GALACTOMANNAN; IMATINIB; METHOTREXATE; NYSTATIN; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ANTIFUNGAL RESISTANCE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPIRATION BIOPSY; BLOOD CULTURE; BRONCHOSCOPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANDIDA KRUSEI; CANDIDA TROPICALIS; CHILD; CHILDHOOD DISEASE; CHILL; CLINICAL ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DIPODASCUS CAPITATUS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; FEVER; FOLLOW UP; FUNGAL DETECTION; FUNGUS CULTURE; FUNGUS IDENTIFICATION; HEMATOLOGIC MALIGNANCY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYPOKALEMIA; HYPONATREMIA; INFANT; KIDNEY DYSFUNCTION; LIVER BIOPSY; LOADING DRUG DOSE; MALE; MONOTHERAPY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; SIDE EFFECT; SKIN BIOPSY; SPLEEN BIOPSY; SPUTUM CULTURE; SURVIVAL RATE; SYSTEMIC MYCOSIS; THORAX RADIOGRAPHY; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, FUNGAL; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; FUNGI; HEMATOLOGIC NEOPLASMS; HUMANS; INFANT; MALE; MYCOSES; PYRIMIDINES; SALVAGE THERAPY; TREATMENT OUTCOME; TRIAZOLES;

EID: 79954467900     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2009.01808.x     Document Type: Article

References (34)

1. Karthaus M, Cornely O. Recent developments in the management of invasive fungal infections in patients with hematological malignancies. Ann Hematol 2005; 84: 207-16.
2. Walsh TJ, Anaissie E, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis 2008; 46: 327-60.
3. Abbasi S, Shenep JL, Hughes WT et al. Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis 1999; 29: 1210-9.
4. Zaoutis TE, Heydon K, Chu JH et al. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006; 117: e711-6.
5. Garcia-Vidal C, Upton A, Kirby KA et al. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47: 1041-50.
6. Crassard N, Hadden H, Piens MA et al. Invasive aspergillosis in a paediatric haematology department: a 15-year review. Mycoses 2008; 51: 109-16.
7. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-66.
8. Herbrecht R, Flückiger U, Gachot B et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haemotological patients. EJC 2007; 5: 49-59.
9. Fortun J, Martin- Davila P, Sanchez MA et al. Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur J Clin Microbiol Infect Dis 2003; 22: 408-13.
10. Walsh TJ, Lutsar I, Driscoll T et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240-8.
11. Cesaro S, Strugo L, Alaggio R et al. Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience. Support Care Cancer 2003; 11: 722-7.
12. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71.
13. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
14. Pannaraj PS, Walsh TJ, Baker CJ. Advances in antifungal therapy. Pediatr Infect Dis J 2005; 24: 921-2.
15. Aliff TB, Maslak PG, Jurcic JG et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97: 1025-32.
16. Cesaro S, Toffolutti T, Messina C et al. Safety and efficacy of caspofungin and liposomal amphotericin B, folllowed by voriconazole in young patients affected by refractory invasive mycosis. Eur J Haematol 2004; 73: 50-55.
17. Baden LR, Katz JT, Fishman JA et al. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 2003; 76: 1632-7.
18. Kontoyiannis DP, Hachem R, Lewis RE et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292-9.
19. Castagnola E, Machetti M, Cappelli B et al. Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukaemia or undergoing allogeneic bone marrow transplant. Clin Microbiol Infect 2004; 10: 255-7.
20. Elanjikal Z, Sörensen J, Schmidt H et al. Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosis. Pediatr Infect Dis J 2003; 22: 653-6.
21. Schuster F, Moelter C, Schmid I et al. Successful antifungal combination therapy with voriconazole and caspofungin. Pediatr Blood Cancer 2005; 44: 682-5.
22. Cesaro S, Giacchino M, Locatelli F et al. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect Dis 2007; 7: 28.
23. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
24. Castagnola E, Caviglia I, Pistorio A et al. Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: a 13-year experience at a single Italian institution. Eur J Cancer 2005; 41: 1439-45.
25. Marchetti O, Cordonnier C, Calandra T. Empirical antifungal therapy in neutropenic cancer patients with persistent fever. EJC 2007; 5: 32-42.
26. Castagnola E, Cesaro S, Giacchino M et al. Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J 2006; 25: 634-9.
27. Rosen GP, Nielsen K, Glenn S et al. Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hematol Oncol 2005; 27: 135-40.
28. Bodey GP, Mardani M, Hanna HA et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002; 112: 380-5.
29. Spanik S, Kaiserova E, Grausova S et al. Fungemia in children with neoplastic diseases. Pediatr Infect Dis J 1998; 17: 442.
30. Maertens J, Vrebos M, Boogaerts M. Assessing risk factors for systemic fungal infections. Eur J Cancer Care (Engl) 2001; 10: 56-62.
31. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-97.
32. Karthaus M, Cornely OA. Second-line treatment in invasive mould infections. Mycoses 2006; 49: 23-26.
33. Pasqualotto AC, Shah M, Wynn R et al. Voriconazole plasma monitoring. Arch Dis Child 2008; 93: 578-81.
34. Walsh TJ, Karlsson MO, Driscoll T et al. Pharmacokinetics and safety of intravenous voriconazole in children after single or multiple dose administration. Antimicrob Agents Chemother 2004; 48: 2166-72.